Opterion Health AG Announces First Patient enrolled in Phase 1 SPARC Trial
Opterion Health AG Announces First Patient enrolled in Phase 1 SPARC Trial Following CTA Approval for OPT101
Transformingdialysis care
Pioneering a non-glucose based dialysis solution designed to make treatment safer, longer-lasting, and more personalized.
scroll downOur Mission
At Opterion, our mission is to relentlessly innovate for those living with chronic kidney disease, creating breakthrough therapies that put patients first — because every person deserves a future free from the burdens of outdated treatments.
A Health CrisisHiding in Plain Sight
Kidney disease affects millions of people worldwide, with many patients ultimately requiring dialysis.
- 25M+ Global Patients
Living with kidney disease worldwide—and growing ~4% per year.
- 3rd Fastest-Growing Cause of Death
Ranking among the top mortality drivers worldwide and still rising.
- A Chronic & Progressive Disease
Fueled globally by the rising rates of diabetes, hypertension, and obesity.
- ~7% of U.S. Medicare Spend
Consuming a massive portion of the healthcare budget to treat less than 1% of the population.
- 30+ Years Without Innovation
The burden of disease has grown, but treatment technology has lagged for decades.
Treating Kidney Disease
For people living with chronic kidney disease, treatment options are limited and life-altering. Improving Peritoneal Dialysis (PD) represents a compelling opportunity to enhance patients' lives while enabling a scalable, cost-effective model for healthcare systems.
Most patients rely on in-center hemodialysis, which is time-consuming, physically demanding, and highly disruptive to daily life. While Peritoneal Dialysis (PD) offers a gentler, at-home alternative linked to better early outcomes, it has seen little innovation in decades. Today's PD is constrained by outdated, glucose-based solutions that cause metabolic stress and limit long-term use.
Understand kidney care
Introducing OPT101
OPT101 is a novel, non-glucose-based osmotic agent designed to address the significant limitations of current PD therapies – improving outcomes and quality of life for patients with advanced chronic kidney disease.
At glance
- Reduces glucose-related complications
- Fewer metabolic side effects
- Safer long-term treatment
- Designed for all daily dwells
- Program progressing, with first data anticipated in mid-2026
Benefits
Fast and consistent
Delivers rapid and sustained ultrafiltration across both day and night dwells.
Metabolically safer dialysis
Minimizes insulin spikes and metabolic stress, making it highly ideal for diabetic patients.
Customizable osmotic strength
Adjustable concentrations allows highly personalized therapy.
Protects kidney function
A gentler alternative that actively preserves the patient's residual kidney function.
Extended treatment duration
Prevents the peritoneal damage caused by glucose, extending the window for PD treatment.
Greater flexibility and freedom
Empowers patients to safely manage their treatment at home, at work, or while traveling.
Join us and be part of our team
We are always looking for dedicated and curious individuals who want to contribute to our mission of advancing breakthrough therapies for patients with chronic kidney disease. Join us and be part of our pioneering spirit.
View Open Roles
Latest Press Releases
Stay up to date with our most recent announcements and development milestones.